Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul 1;151(7):665-672.
doi: 10.1001/jamaoto.2025.0903.

ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical Trial

David M Routman  1 , Kathryn M Van Abel  2 , Katharine A Price  3 , Eric J Moore  2 , Samir H Patel  4 , Michael L Hinni  5 , Briant Fruth  6 , Nathan R Foster  6 , Linda X Yin  2 , Michelle Neben-Wittich  1 , Yolanda I Garces  1 , Lisa A McGee  4 , Scott C Lester  1 , Mauricio E Gamez  1 , Jean-Claude M Rwigema  4 , Adam L Holtzman  7 , Daniel L Price  2 , Jeffrey R Janus  8 , Jan L Kasperbauer  2 , Ashish V Chintakuntlawar  9 , Joaquin J Garcia  10 , Robert L Foote  1 , Daniel J Ma  1
Affiliations
Clinical Trial

ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical Trial

David M Routman et al. JAMA Otolaryngol Head Neck Surg. .

Abstract

Importance: The De-escalated Adjuvant Radiation Therapy (DART) phase 3 randomized clinical trial (RCT) showed that in patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma, postoperative minimal residual disease (MRD), detected through circulating tumor HPV DNA (ctHPVDNA), was associated with a higher risk of disease progression. When considered along with pathologic factors, postoperative ctHPVDNA assessment may improve patient selection for adjuvant treatment de-escalation; however, more data are needed to demonstrate how it may be used in personalizing treatment intensity.

Objective: To determine the association of postoperative MRD status with progression-free survival (PFS) after surgery for HPV-associated oropharyngeal squamous cell carcinoma.

Design, setting, and participants: This was a secondary analysis of the DART RCT, which was conducted from October 2016 to August 2020 in multiple sites in the US. Participants from the de-escalated adjuvant radiation therapy group and the standard of care group with available blood specimen data were included. Reports from 3-month posttreatment surveillance visits were used to assess associations and outcomes. Data analyses were performed from March 2023 to March of 2025.

Interventions: The DART group received 30 to 36 Gy of radiation therapy in 1.5 to 1.8 Gy twice daily, plus docetaxel, 15 mg/m2, on days 1 and 8. The standard of care group received 60 Gy with or without weekly cisplatin, 40 mg/m2.

Main outcome and measure: PFS.

Results: The analysis included 140 patients (mean [SD] age, 59.1 [8.4] years; 12 [8.6%] females and 128 [91.4%] males; 97 [69.3%] with no smoking history); characteristics were similar to the overall DART RCT population. Of these, 17 patients (12.1%) had postoperative MRD (13 of 96 [13.5%] receiving DART and 4 of 44 [9.1%] receiving standard of care). For all patients, postoperative MRD positivity was strongly associated with worsened PFS at 24 months (MRD positivity, 69.5%; MRD negativity, 95.9%; hazard ratio [HR], 0.19; 95% CI, 0.06-0.59). MRD positivity was associated with PFS when evaluating only those patients in the DART group, where 24-month PFS was 68.4% compared to 92.6% for MRD-negative patients (HR, 0.28; 95% CI, 0.08-0.93). Three months after completion of all treatment, 8 of 117 patients (6.8%) had detectable ctHPVDNA, whereas 109 of 117 (93.2%) did not, and detection was highly associated with PFS (HR, 20.48; 95% CI, 6.91-60.67).

Conclusions and relevance: This secondary analysis of the DART RCT found that patients with detectable ctHPVDNA after surgery had a higher risk of disease progression. When added to the pathologic factors considered, ctHPVDNA assessment may improve selection of patients for treatment de-escalation. In addition, the 3-month posttreatment time point, early in surveillance, may identify a sizable portion of patients with progression and may guide intervention and surveillance after surgery for HPV-associated oropharyngeal squamous cell carcinoma.

Trial registration: ClinicalTrials.gov Identifier: NCT02908477.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Routman reported advisory board membership for Adela, with renumeration to Mayo Clinic outside the submitted work; a patent for DNA methylation licensed to Exact Sciences; and support from the Paul Calabresi Program in Clinical/Translational Research at the Mayo Clinic Comprehensive Cancer Center (K12CA090628). Dr Patel reported personal fees from Galera Therapeutics outside the submitted work. Dr Lester reported royalties from Empyrean Medical outside the submitted work. Dr D. Price reported nonfinancial support from In Situ Biologics outside the submitted work. No other disclosures were reported.

Comment on

References

    1. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.3007094 - DOI - PMC - PubMed
    1. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548-554. doi: 10.1038/nm.3519 - DOI - PMC - PubMed
    1. Dasari A, Grothey A, Kopetz S. Circulating tumor DNA-defined minimal residual disease in solid tumors: opportunities to accelerate the development of adjuvant therapies. J Clin Oncol. 2018;36(35):JCO2018789032. doi: 10.1200/JCO.2018.78.9032 - DOI - PMC - PubMed
    1. Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021;11(12):2968-2986. doi: 10.1158/2159-8290.CD-21-0634 - DOI - PMC - PubMed
    1. Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J Clin Oncol. 2022;40(6):567-575. doi: 10.1200/JCO.21.01929 - DOI - PMC - PubMed

Substances

Associated data